Description:
<jats:sec><jats:title>Introduction</jats:title><jats:p>Early-stage accurate diagnosis of malignant pleural mesothelioma (MPM) has always been a formidable challenge. DNA and protein as biomarkers for the diagnosis of MPM have received considerable attention, and yet the outcomes are inconsistent.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>In this study, a systematic search employing PubMed, EMBASE, and Cochrane Library to identify relevant studies from the first day of databases to October 2021. Moreover, we adopt the QUADAS-2 to evaluate the quality of eligible studies and Stata 15.0 and Review Manager 5.4 software programs to perform the meta-analysis. Additionally, bioinformatics analysis was performed at GEPIA for the purpose of exploring relationship between related genes and the survival time of MPM patients.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We included 15 studies at the DNA level and 31studies at the protein level in this meta-analysis. All results demonstrated that the diagnostic accuracy of the combination of MTAP + Fibulin-3 was the highest with the SEN 0.81 (95% CI: 0.67, 0.89) and the SPE 0.95 (95% CI: 0.90, 0.97). And the bioinformatics analysis indicated that the higher MTAP gene expression level was beneficial to enhance the survival time of MPM patients.</jats:p></jats:sec><jats:sec><jats:title>Discussion</jats:title><jats:p>Nonetheless, as a result of the limitations of the included samples, it may be necessary to conduct additional research before drawing conclusions.</jats:p></jats:sec><jats:sec><jats:title>Systematic review registration</jats:title><jats:p><jats:ext-link>https://inplasy.com/inplasy-2022-10-0043/</jats:ext-link>, identifier INPLASY2022100043.</jats:p></jats:sec>